We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Destiny Pharma Plc | DEST | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 18.25 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 18.25 | 18.25 | 18.25 | 18.25 | 18.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 26/4/2024 11:51 by carlisle44 Brian, we knew since last year that talks have been in tow as such I think Dest were right to say that it has listened and learned and that its strategic review now enables it to re-engage with greater prospects (halving the Trial costs being, it seems to me pivotal). If it had remained silent as to where we are then uncertainty would, in my view have been rampant.edmona thank you for posting the note above. |
Posted at 21/4/2024 07:01 by simonlevert IIG absolutely could look at a stake in DEST given their track record. If the public market doesn’t value companies like this then private equity and VC’s will hxxps://iigplc.com/b |
Posted at 16/4/2024 18:54 by wh1spa Could Sir Nigel's IIG take a significant stake in DEST - Chairman of both so perhaps it's a non starter or at least would somehow have to be at arms length re valuations etc. |
Posted at 10/4/2024 15:29 by banshee The CEO's decision to push reformulation of M3 to the point where a rerun of Phase 2 may be required continues to look inexplicable. The emphasis on exploring all options to optimise value in recent RNS' does hint a going private as a possibility but their share holder register, with no large 10%+ holdings, might make getting support for it problematic. Once xf-73 dermal gets into Phase 1 for diabetic ulcers and burns things will look a bit better.ODT have been pusing their (very decent) tech for 10 years or more with neglible revs and no cash plus a similar burn rate to DEST. Neither co looks a good buy at the moment imo. Not clear whether either co can attract someone to fund a US P3 trial. Dest are at least in talks, ODT don't seem to be. |
Posted at 28/3/2024 11:47 by john henry Dest have enough cash until Q2 2025.My guess is that they would conclude the JV before raising further funds. Saying that funding requirements will depend on the upfront cash payment from the JV. |
Posted at 28/3/2024 11:28 by beatme1 Dest has decided to go private and are following in c4xd footsteps |
Posted at 05/3/2024 22:13 by bones698 So educational I take it your under water here amerpoo. You have picked quite a few dogs recently with apta, dest etc. Crawl back into your hole gobshjte |
Posted at 05/3/2024 14:11 by bones698 Marvel man there is one real bones and an imposter with 699 after his name who I upset because I showed everyone he was an idiot and no trolls the boards using that name. So be careful which you follow an dlok at.As for dest I said sub 30p and it had got there and looks likely to head lower without news. It was overvalued for where it was upto and the cash requirements and time it will take. That hasn't changed, be careful with biotech shares they are cash hungry in a market where cash isn't available. As for my AGL all mine are free as I bought near the lows and sold on the spike keeping the rest free. Not many at win such a position |
Posted at 05/2/2024 14:33 by john henry Candid on LSEThe RNS was indeed positive but some may have perceived the possibility of a bridging phase 2 trial by Sebela as a delay. This might not even happen as the RNS stated that Sebela are evaluating it and MAY decide to run a bridging phase 2 before doing the phase 3. I think they might in fact evaluate it and then go into phase 3 after doing a simple test to show equivalence as there is already an FDA agreement in place for exactly this reason. (DEST presentation 2023): Process development ongoing to produce oral capsule product for Phase 3 — FDA agreed to simple disintegration test to demonstrate equivalence between Phase 2 and Phase 3 product — Expected to have capsules ready for Phase 3 H2 2023 Therefore Sebela may only need to before a simple test to demonstrate equivalence and M3 is back on track. Dest having been working on an oral capsule for months. |
Posted at 02/2/2024 14:29 by banshee JH The reformulation is under the remit i.e authority and control - of Dest, following their own review. The only reference to Sebal being involved is that that have had/agreed to change their manufacturing and control contract alongside Dest. It may be that they are happy to simply rerun phase 2, but also possible this will trigger an internal re-review of the project if that is the option recommended. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
